NVCR News and Press, NovoCure Limited From 11/24/20

Shares of Novocure (NASDAQ: NVCR) were sinking 9.2% as of 3:30 p.m. on Tuesday. The oncology therapy company didn't announce any news, so why did the stock fall on a day when the overall market soared? The most likely reason is that some investors decided to lock in profits after No...

Two new breakout stocks for Week 48 with better than 10% short-term upside potential. This past week, two out of four stocks gained over 10% led by peak gains in VERI +48.6% and FLGT +22.4% with avg portfolio gains of +12%. The streak of weekly picks gaining over 10% in less than ...

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-...

Palm Beach, FL – November 17, 2020 – With the increasing prevalence of brain cancer, rising aging population, and growing incidences of cancer via chemical exposure, the demand of diagnosis and treatment of brain tumors is steadily increasing. The diagnosis, treatments, therap...

Novocuore has disruptive technologies in cancer treatments. The company has enormous room for growth if management delivers. Revenue growth is accelerating. The stock is not too expensive considering the company's growth prospects. The nature of the business is intrinsical...

Novocure (NVCR) has received the CE Mark for the NovoTTF-100L system, for the commercialization of the device as a first-line treatment in combination with Eli Lilly's Alimta (pemetrexed) and platinum-based chemotherapy for malignant pleural mesothelioma ((MPM)), in the Europea...

Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investo...

Provides flexible capital structure prior to anticipated period of significant innovation and growth Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 millio...

Initial conversion price represents a premium of approximately 50% Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of $575 million ...

Novocure (NVCR) has priced $500M of its 0% convertible senior unsecured notes due November 1, 2025 through a private placement.Initial purchasers granted an option to purchase additional $75M of notes.Closing date is November 5. Special interest on the notes, if any,  will be payabl...